Trial Profile
A Single-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Multiple Doses of E5555 on the Pharmacokinetics of Metformin (a Substrate for OCT2 Transporter) and on Renal Function in Healthy Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Atopaxar (Primary) ; Metformin
- Indications Diabetes mellitus; Thromboembolism
- Focus Pharmacokinetics
- Sponsors Eisai Inc
- 31 Jan 2012 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.
- 31 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 25 Nov 2010 New trial record